This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Ascentage Pharma (Suzhou) Co., Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Guoqin Zhai: Innovator in Cancer Treatment
Introduction
Guoqin Zhai is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of medical research, particularly in the development of innovative treatments for diseases such as cancer. His work focuses on combining various inhibitors to enhance therapeutic efficacy.
Latest Patents
Guoqin Zhai holds a patent for a combination product of a Bcl-2 inhibitor or a Bcl-2/Bcl-xL dual inhibitor and a BTK inhibitor. This combination product is designed for use in the prevention and/or treatment of diseases, including cancer, autoimmune diseases, and inflammatory diseases. The patent highlights the potential of this innovative approach to improve patient outcomes.
Career Highlights
Throughout his career, Guoqin Zhai has worked with notable companies in the pharmaceutical industry, including Ascentage Pharma (Suzhou) Co., Ltd. and Ascentage Pharma Co., Ltd. His experience in these organizations has allowed him to contribute to groundbreaking research and development efforts.
Collaborations
Guoqin Zhai has collaborated with esteemed colleagues such as Dajun Yang and Yifan Zhai. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Guoqin Zhai's work exemplifies the spirit of innovation in the medical field. His contributions to the development of combination therapies hold promise for advancing treatment options for various diseases. His dedication to research continues to inspire future advancements in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile